 |
|
Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
Seong Woo Go, Boo Kyeong Kim, Sung Hak Lee, Tae-Jung Kim, Joo Yeon Huh, Jong Min Lee, Jick Hwan Hah, Dong Whi Kim, Min Jung Cho, Tae Wan Kim, Ji Young Kang
Tuberc Respir Dis. 2013;75(6):256-259. Published online 2013 Dec 24 DOI: https://doi.org/10.4046/trd.2013.75.6.256
|
|
Citations to this article as recorded by
 Treatment dilemmas in patients with gastrointestinal stromal tumors (GIST) who experienced imatinib-induced pneumonitis: A case series
Deborah van de Wal, Evelyne Roets, Roos F. Bleckman, Jorn Nützinger, Birthe C. Heeres, J. Martijn Kerst, Mahmoud Mohammadi, Anna K.L. Reyners, Ingrid M.E. Desar, Astrid W. Oosten, Neeltje Steeghs, Winette T.A. van der Graaf
Current Problems in Cancer: Case Reports.2024; 13: 100280. CrossRef Imatinib-induced irreversible interstitial lung disease
Ping Zhang, Jingfeng Huang, Fangfang Jin, Jiaohai Pan, Guifang Ouyang
Medicine.2019; 98(8): e14402. CrossRef Imatinib mesylate in the management of chemotherapy-induced pulmonary toxicity: a double-edged sword
Ahmet Emre Eskazan
Acta Oncologica.2019; 58(1): 123. CrossRef Pneumonitis After Precision Oncology Therapies: A Concise Review
Akash Jain, Vickie R. Shannon, Ajay Sheshadri
Journal of Immunotherapy and Precision Oncology.2018; 1(1): 26. CrossRef European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
J L Steegmann, M Baccarani, M Breccia, L F Casado, V García-Gutiérrez, A Hochhaus, D-W Kim, T D Kim, H J Khoury, P Le Coutre, J Mayer, D Milojkovic, K Porkka, D Rea, G Rosti, S Saussele, R Hehlmann, R E Clark
Leukemia.2016; 30(8): 1648. CrossRef Tyrosine Kinase Inhibitor-Induced Interstitial Lung Disease: Clinical Features, Diagnostic Challenges, and Therapeutic Dilemmas
Rashmi R. Shah
Drug Safety.2016; 39(11): 1073. CrossRef Imatinib
Reactions Weekly.2014; 1521(1): 85. CrossRef
|